From Yahoo Finance: 2025-03-21 12:17:00

Stifel analyst Alex Thompson raised Immunovant’s price target to $61 from $58, maintaining a Buy rating after positive data from two studies. The firm believes IMVT-1402 is a low-risk asset in the fragment crystallizable receptor space. Stifel updated its model to reflect IMVT-1402 as the lead in MG/CIDP.

Read more: Immunovant price target raised to $61 from $58 at Stifel